Abstract
The manufacture of lentiviral vectors (LVVs) is currently a bottleneck for the development of cell and gene therapies. Typical upstream and downstream processes are often low-yielding, unscalable, involve many manual operations, and are poorly characterized. In this article, we describe the potential that LVV stable producer cell lines offer when used in upstream processes based upon suspension culture systems, and the implications that this can have on downstream unit operations. We also describe potential areas for innovation in order to develop LVV manufacturing processes suitable for commercial supply of potentially transformative cell and gene therapy medicines.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
